﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Advanced Pharmaceutical Bulletin</JournalTitle>
      <Issn>2228-5881</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month>04</Month>
        <DAY>15</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>An Optimized Method for Single Cell Cloning of Human CAR-T Cells Based on FBS-Coated Plates</ArticleTitle>
    <FirstPage>133</FirstPage>
    <LastPage>142</LastPage>
    <ELocationID EIdType="doi">10.34172/apb.43798</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Mahdie</FirstName>
        <LastName>Jafari</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-0991-1818</Identifier>
      </Author>
      <Author>
        <FirstName>Shahriyar</FirstName>
        <LastName>Abdoli</LastName>
      </Author>
      <Author>
        <FirstName>Masoud</FirstName>
        <LastName>Moghaddam Pour</LastName>
      </Author>
      <Author>
        <FirstName>Mohammad Ali</FirstName>
        <LastName>Shokrgozar</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0001-5123-4155</Identifier>
      </Author>
      <Author>
        <FirstName>Zahra</FirstName>
        <LastName>Sharifzadeh</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-4419-0315</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/apb.43798</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2024</Year>
        <Month>09</Month>
        <Day>19</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>12</Month>
        <Day>21</Day>
      </PubDate>
    </History>
    <Abstract>Purpose: T cell-based immunotherapy, especially chimeric antigen receptor (CAR)-T cells, has emerged as an appropriate approach for treating hematologic malignancies and is currently under investigation in clinical trials for solid tumors. Despite significant improvements in CAR-T cell production processes, the isolation and expansion of CAR-engineered T cells continue to pose significant challenges. The aim of this research is to provide a simple and cost-effective method for the isolation and expansion of human CAR-T cells. This novel concept applies coated fetal bovine serum (FBS) culture plates and focuses on enhancing viability and functionality to improve the adherence of suspended T cells. Methods: This study evaluated a two-dimensional (2D) culture technique for isolating the CAR-T cells that target prostate-specific membrane antigen (PSMA) utilizing matrices pre-coated with 0.2% glutaraldehyde and FBS. Jurkat cells were transduced with a lentiviral vector encoding the anti-PSMA CAR construct. FBS-coated and commercialized Matrigel-coated matrices were used for single-cell isolation and clonal expansion. Functional tests were conducted to assess the activation and proliferation of CAR-T cells and the IFN-γ release assay subsequent to cloning and expansion. Results: Transfection efficiency markedly improved, with 88.4% of Lenti-X 293T cells demonstrating green fluorescent protein (GFP) expression. Among the Jurkat cells, 57.1% showed GFP expression post-transduction, of which 34.1% showed surface expression of anti-PSMA CAR. Clonal expansion on the FBS-coated matrix proved effective, yielding 92.1% GFP-positive isolated cells. Functional assays demonstrated that CAR-T cells co-cultured with LNCaP cells exhibited significantly enhanced proliferation, activation (as indicated by CD69 and CD25 expression), and cytokine release assay (IFN-γ) compared with those co-cultured with DU 145 and mock cells. Conclusion: This new approach is efficient, economical, and scalable for isolating specific homogenous T cells and promoting their clonal proliferation and expansion. Furthermore, this method improves T cell adherence, proliferation, and functional effectiveness, offering a potential foundation for advancing CAR-T cell therapies aimed at solid tumors. Future research should concentrate on optimizing culture conditions and testing this method in preclinical animal models to ensure its clinical applicability and efficacy.  </Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cancer immunotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CAR-T cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Clonal expansion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">2D culture system</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">FBS coating</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Single cell isolation</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>